- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02559674
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Phase Ib/II Study of ALT-803 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Pancreatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate the safety and tolerability of escalating doses, to identify the Maximum Tolerated Dose (MTD) and designate a dose level for Phase II study (RP2D) of ALT-803 administered in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.
To access the anti-tumor activity of ALT-803 administered in combination with gemcitabine and nab-paclitaxel as measured by objective response rate, overall survival, progression-free survival, time to progression, and duration of response in patients with advanced pancreatic cancer.
To Characterize the pharmacokinetic, immunogenicity, and serum cytokine profile of ALT-803 in combination with gemcitabine and nab-paclitaxel in treated patients. To correlate circulating cell free DNA and circulating tumor DNA with clinical outcomes of the study in treated patients.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- University of Hawaii Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Inclusion Criteria:
Histologically or cytologically confirmed diagnosis of pancreatic cancer.
- For dose escalation phase (Phase Ib) distant metastatic disease or unresectable disease and not a candidate for down staging to resection.
- For expansion phase (Phase II) distant metastatic disease only.
- For dose escalation phase (Phase Ib) 0 or 1 prior lines of chemotherapy for advanced pancreatic cancer. Prior gemcitabine is allowed, however prior nab-paclitaxel is not allowed.
- For expansion phase (Phase II) no prior therapy for pancreatic cancer is allowed except for adjuvant therapy as long as it was completed ≥ 6 months prior to study treatment start
- Have at least one untreated and progressing tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumor
- Prior radiation is allowed if the index lesion(s) remains outside of the treatment field or has progressed since prior treatment. Radiation therapy must have been completed at least 4 weeks prior to the baseline scan
- Resolved acute effects of any prior therapy to baseline or Grade ≤1
- The Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
- Life expectancy ≥12 weeks
- Glomerular Filtration Rate (GFR) > 40mL (milliliter)/min; Creatinine ≤ 1.5 x ULN (Upper limit of Normal)
- Platelets ≥100,000/uL (microliter)
- Hemoglobin ≥ 9g/dL
- Absolute Lymphocytes ≥800/uL
- Absolute neutrophil count/absolute granulocyte count ≥1500/uL
- Total bilirubin ≤ 2.0 X ULN, or ≤ 3.0 X ULN (for patients with Gilbert's Syndrome)
- aspartate aminotransferase, alanine aminotransferase ≤ 2.5 X ULN, or ≤ 5.0 X ULN (if liver metastasis present)
- Normal clinical assessment of pulmonary function
- Negative serum pregnancy test if female and of childbearing potential
- Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study
- Must provide informed consent and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations
Exclusion Criteria:
- No women who are pregnant or nursing
- No known hypersensitivity to gemcitabine or nab-paclitaxel
- No concurrent herbal or unconventional therapy
- No prior therapy with IL-15 or IL-15 analog
- No ongoing toxicity from prior anti-cancer treatment that may interfere with study treatment. All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must resolve to grade 1 or baseline before administration of the study treatment.
- No positive Hep C serology or active Hep B infection
- No congestive heart failure < 6 months
- No unstable angina pectoris < 6 months
- No myocardial infarction < 6 months
- No history of ventricular arrhythmias or severe cardiac dysfunction
- No history of uncontrollable supraventricular arrhythmias
- No New York Heart Association Class > II congestive heart failure
- No marked baseline prolongation of QT/QTc interval
- No known autoimmune disease requiring active treatment. Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
- No known prior organ allograft or allogeneic transplantation
- No known HIV-positive or AIDS unless patient is on a stable highly active antiretroviral therapy (HAART) regimen, have CD4 (cluster of differentiation 4) counts >350, with no detectable viral load on quantitative polymerase chain reaction test
- No untreated central nervous system metastases, or if treated must be neurologically stable for at least 2 weeks prior to enrollment
- No corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent)
- No psychiatric illness/social situation that would limit compliance
- No other illness that in the opinion of the investigator would exclude the subject from participating in the study
- No active systemic infection requiring parenteral antibiotic therapy
- No anti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days before treatment start
- No disease requiring systemic immunosuppressive therapy
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 3 years after surgical treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Phase Ib/II ALT-803 w/ gemcitabine and nab-paclitaxel
|
Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43.
Eligible patients may receive up to 10 additional treatment cycles.
Other Names:
Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43.
Eligible patients may receive up to 10 additional treatment cycles.
Other Names:
Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44.
Eligible patients may receive up to 10 additional treatment cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of MTD; Phase Ib
Time Frame: 9 Months
|
Determine the maximum tolerated dose (MTD) level and designate the recommended dose level for phase II.
|
9 Months
|
Safety Profile (Number and severity of treatment related AEs); Phase Ib and II
Time Frame: 48 Months
|
Number and severity of treatment related adverse events (AEs) that occur or worsen after the first dose of study treatment
|
48 Months
|
Overall Survival; Phase II
Time Frame: 8.5 Months
|
Determine the 8.5 month overall survival of treated patients
|
8.5 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: 72 Months
|
Evaluate objective response rate in treated patients.
|
72 Months
|
Duration of response
Time Frame: 72 Months
|
Evaluate duration of response in treated patients.
|
72 Months
|
Time to progression
Time Frame: 72 Months
|
Evaluate time to progression in treated patients.
|
72 Months
|
Progression-free survival
Time Frame: 72 Months
|
Evaluate progression-free survival in treated patients.
|
72 Months
|
Biomarkers; Phase Ib
Time Frame: 36 Months
|
Measure the serum levels of the following including but not limited to Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-6 (IL-6), Interleukin-10 (IL-10), Interferon-gamma (IFN-ɣ), Tumor necrosis factor-alpha (TNF-α) and Monocyte chemoattractant protein-1 (MCP-1)
|
36 Months
|
Determine the level of anti-ALT-803 antibodies in patient serum
Time Frame: 36 Months
|
Determine the level of anti-ALT-803 antibodies in patient serum
|
36 Months
|
Area under the plasma concentration-time curve from time zero to infinity (AUC); Phase Ib
Time Frame: 36 Months
|
Area under the plasma concentration-time curve from time zero to infinity (AUC)
|
36 Months
|
Correlation between the level of circulating cell free DNA in patient plasma and response to study treatment
Time Frame: 36 Months
|
Correlation between the level of circulating cell free DNA in patient plasma and response to study treatment
|
36 Months
|
Correlation between the level of tumor DNA in patient plasma and response to study treatment
Time Frame: 36 Months
|
Correlation between the level of tumor DNA in patient plasma and response to study treatment
|
36 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Hing C. Wong, Ph.D., Altor BioScience
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Gemcitabine
- Paclitaxel
Other Study ID Numbers
- CA-ALT-803-01-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Pancreatic Cancer
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
Danae Hamouda, MDRecruitingAdvanced Solid Tumor | Advanced Pancreatic CancerUnited States
-
Rui-hua Xu, MD, PhDNot yet recruitingAdvanced Pancreatic CancerChina
-
Mayo ClinicNational Cancer Institute (NCI)CompletedAdvanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Pancreatic Neoplasm | Locally Advanced Pancreatic CarcinomaUnited States
-
Istituto Scientifico Romagnolo per lo Studio e...CompletedUnresectable Pancreatic Cancer | Locally Advanced Pancreatic Cancer | Nonmetastatic Pancreatic CancerItaly
-
University of UtahNational Cancer Institute (NCI)Active, not recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal...United States
-
National Cancer Institute (NCI)SuspendedStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Locally Advanced Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Unresectable Pancreatic AdenocarcinomaUnited States
-
Centre Leon BerardRecruitingMetastatic Pancreatic Cancer | Advanced Pancreatic CancerFrance
-
Washington University School of MedicineNational Cancer Institute (NCI)RecruitingCervical Cancer | Pancreatic Cancer | Pancreas Cancer | Locally Advanced Cervical Carcinoma | Locally Advanced Cervical Cancer | Cancer of the Pancreas | Locally Advanced Pancreatic Carcinoma | Locally Advanced Pancreatic Cancer | Cancer of the Cervix | Locally Advanced Pancreas CancerUnited States
-
Azienda Ospedaliero-Universitaria di ModenaRecruitingMetastatic Pancreatic Cancer | Advanced Pancreatic CancerItaly
Clinical Trials on Gemcitabine
-
AstraZenecaRecruitingBiliary Tract CancerFrance, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
-
Sierra Oncology LLC - a GSK companyCompletedAdvanced Solid TumorsSpain, United Kingdom
-
University of Erlangen-Nürnberg Medical SchoolActive, not recruiting
-
Shenzhen University General HospitalNot yet recruiting
-
3D Medicines (Sichuan) Co., Ltd.Not yet recruitingBiliary Tract Neoplasms
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
3D Medicines (Sichuan) Co., Ltd.RecruitingBiliary Tract NeoplasmsChina
-
Kansai Hepatobiliary Oncology GroupCompleted
-
Air Force Military Medical University, ChinaRecruiting
-
SUNHO(China)BioPharmaceutical CO., Ltd.Recruiting